Skip to main content
ホーム / コンテンツ / イベント / 2022 AAPS PharmSci 360

2022 AAPS PharmSci 360

2022 AAPS PharmSci 360
Speakers & Posters
We are excited to be presenting at this conference
AAPS PharmSci 360 eCalk Talk: Avoid getting “lost in translation”- Increase confidence in translational research using biosimulation
Mark Lovern, PhD |
One of the pivotal milestones of early drug development is obtaining approval for an investigational new drug application (IND). A proposed first-in-human (FIH) study design is required for every IND application, of which a robust FIH dose rationale is a critical component. Physiologically-based pharmacokinetic (PBPK) modeling is a methodology based upon in-depth mechanistic understanding of the biological and pharmacologic phenomena which determine in vivo PK in animals and humans. Consequently, PBPK models are well-posed to make robust predictions of in vivo PK exposures, even when based on the limited data available during the initial stages of drug development. As such, PBPK approaches are being increasingly employed to strengthen the FIH dose rationale. Other applications of PBPK in early development include guiding early formulation development and facilitating lead candidate selection. This eChalk Talk will focus on how PBPK modeling can be applied during early drug development with a particular focus on optimal FIH candidate and dose selection, thereby enhancing the odds of a successful IND and subsequent clinical development.
The Skills You Need to be a Pharmaceutical Consultant
Suzanne Minton, PhD; Mark Lovern, PhD; David Mitchell, PhD; Jill Fiedler-Kelly; Alexander Berg; Ben Suttle |
Have you been interested in a career as a pharmaceutical consultant but didn’t know how to get started? Maybe you’ve got questions on whether you’re experienced enough to be considered seriously by hiring managers? Or you’re currently in a position in academia, industry, or a regulatory agency, and want to make a transition to consulting but don’t know when the best time is? Perhaps you’re wondering if consulting can provide a stable career path? If you’re asking yourself any of these questions, then this is the career development session for you!
(M0930-11-65) A Mechanistic PBPK Model for Maraviroc to Elucidate the Dose Related Non-Linearity in Oral Absorption using a Middle-Out Approach
Amin Rostami-Hodjegan, PharmD, PhD |
Meet the Employer Roundtable
Nathalie Rioux and Sebastian Polak |
Location: Career Center
(M1130-10-57) Development and Verification of Physiologically-Based Pharmacokinetic (PBPK) Model for Vaginal Administration of Dapivirine Ring and Gel Formulation
Sebastian Polak, Ph.D. |
(M1130-01-05) Evaluating Influence of Critical Quality Attributes of Metronidazole Topical Gel on Bioequivalence Using the Dermal Virtual Bioequivalence (VBE) Module in Simcyp Simulator
Krishna Chaitanya Telaprolu, Ph.D. |
[Rapid Fire] Rapid Repurposing of a QSP Platform to Guide COVID-19 Vaccine Development
Piet van der Graaf, PharmD, PhD |
Location: 151 AB
Applications of PBPK for Virtual BE Assessment of Dermal Products
Sebastian Polak, PhD |
Physiologically Based Pharmacokinetic (PBPK) models can be used to virtually assess the formulation's bioequivalence (VBE). These applications cover a wide range of oral, dermal, inhalation as well as long-acting injectable formulations. Such capabilities present opportunities and challenges in informing, optimising and saving many unnecessary BE studies. In addition, it allows expanding BE studies beyond healthy populations within a patient-centric paradigm. To enable PBPK modeling for regulatory decision-making, models should be sufficiently qualified and verified for the intended purpose. In this session, the state of the arts in using PBPK models for VBE studies, requirements, and case studies are presented.
(T1130-11-64) Physiologically Based Pharmacokinetic Modelling to Predict the Pharmacokinetics of Aspirin and Its Metabolite Salicylic Acid after Intravenous, Oral, and Rectal Administration
Santosh Puttrevu, Ph.D. |
Keynote: Applications of MIDD for Dose Selection, Specific Populations, and Beyond: The Advantages of Bracketing
Julie Bullock, PharmD; Amit Desai, Ph.D. |
Bracketing is an often overlooked approach to not only justify a dose regimen, but to also put into context exposure differences for specific populations and extrinsic factors. Case studies of MIDD approaches and how they can be applied to these scenarios will be discussed and the benefits of bracketing to the overall development program both pre and post approval will be outlined.
Lost in translation? Predict first-in-human PK with Simcyp Discovery
Hannah Jones, PhD |
The attrition rate of drug programs in early-stage development is high, with two-thirds of preclinical programs failing to move successfully to Phase 1. How do we better inform translational R&D decisions to de-risk investments and help increase probability of success? Physiologically-based pharmacokinetic (PBPK) modeling and simulation is a regulatory-adopted, versatile tool in drug development that helps answer a myriad of “what if” questions without clinical testing. Join this session to learn how to use Simcyp Discovery Simulator for first-in-human dose prediction.
Indulge in the Taste of Boston
Certara Team |
Take your taste buds on tour of Boston’s most iconic flavors—without leaving the conference! Stop by the Certara booth from 2:30 pm – 3:30 pm to experience some of the most delicious clam chowders Boston has to offer.
[Rapid Fire] A Novel Mechanistic Model for Drug Release from PLGA Implants
Santosh Kumar Puttrevu, PhD |
Location: 151 AB
Supporting Biowaivers with PBPK Virtual Bioequivalence: Importance of Within-Subject Variability
Amin Rostami-Hodjegan, PharmD, PhD |
Location: 151 AB
Exponentially Expanding Science: Applications and Regulatory Acceptance of PBPK Modeling
Hannah Jones, PhD |
There should no longer be any question as to the value and myriad benefits of PBPK in drug discovery and development. With the publication of two new ICH and one new FDA guidance documents this past week that incorporate its use, we can affirm that global regulators are bullish on the use of PBPK in an ever-increasing type of use cases. In 2018, a chart was published by the US FDA (with a similar one from EMA) that used a green/amber/red light approach to communicating their openness to using PBPK for regulatory approval. Since that time, there have been many areas and use cases for which the regulators have upgraded that approach (amber to green for example), as documented in new drug approvals and published papers. Additionally, the acceptance and encouragement has expanded across the drug development continuum, with increased use cases in discovery, translation to FIH, across all clinical trials, and for post-marketing label expansion.
Assignment of Within-Subject Variability During PBPK Based Virtual Bioequivalence Studies
Amin Rostami-Hodjegan, PharmD, PhD |
The concept of “Virtual Bioequivalence” (V-BE) is built on the back of combination physiologically-based (PBPK) modelling, integration of results from in vitro tests on drug product, use of pre-existing data on systems and drug. The subject is growing out of its infancy as multiple applications are now reported in the literature. Passing the BE criteria involves showing similarity in systemic exposure (pharmacokinetic profile - PK) following the administration of the test and reference products. However, indicating equivalence for average profile is not adequate and the degree of population variability around the average, by means of 90% confidence interval (CI), needs to be within certain range of the reference product (typically 80-125%). The presentation aims to demonstrate the differences between various strategies that help to capture the CI around the PK profile during conduct of VBE studies. The study highlights the propagating physiological within-subject variability (WSV) to PK profiles and how these might be different for test and reference products.
Phoenix Lunch & Learn
Join us from 12:00 pm – 1:30 pm to learn how you can streamline your PK/PD analyses while enjoying a complimentary lunch. Our experts will introduce the newly launched Phoenix WinNonlin® Hosted, share Phoenix WinNonlin® tips and tricks, and reveal the exciting new features from the latest PK Submit release.
A Quantitative Systems Toxicity Workflow to Model Adverse Outcome Pathways’ Biomarkers
Sebastian Polak, PhD |
Location: 152
Miscomprehensions on Quantitative Liquid Biopsy as Biomarkers of Hepatic ADMET Proteins
Amin Rostami-Hodjegan, PharmD, PhD |
Location: 152
Powered by GlobalLink OneLink Software